Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Measles and Mumps Combined Vaccine, Live (SIBP) is a live attenuated combination vaccine developed to provide active immunization against measles and mumps. The vaccine contains weakened forms of the measles virus and the mumps virus that stimulate the immune system to produce protective antibodies without causing disease. Upon administration, it induces an immune response resulting in long-lasting immunity against both viruses. This vaccine is primarily indicated for the prevention of measles and mumps infections in children. It is developed by Shanghai Institute of Biological Products Co., Ltd., which is also known for producing a combined measles, mumps, and rubella (MMR) vaccine[4]. The SIBP formulation does not include rubella.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Measles and Mumps Combined Vaccine, Live (SIBP).